CA
NZ
UK
AU
IND
US
AbbVie (NYSE: ABBV) announced U.S. FDA approval for Skinvive by Juvederm, a novel hyaluronic acid injectable for neck wrinkles, alongside updated Phase 3 data demonstrating durable efficacy in chronic lymphocytic leukemia.Key HighlightsAbbVie (NYSE: ABBV) received FDA approval for Skinvive by Juvederm, the first hyaluronic …
Codexis (NASDAQ: CDXS) shareholders finalized their annual meeting decisions, endorsing the company’s proposed board of directors without dissent. The vote reaffirms investor alignment with management’s long-term strategy in the biocatalysis sector. The outcome removes near-term governance uncertainty for the biotech firm.
Enliven Therapeutics has captured investor attention with its experimental oncology treatments, which aim to address unmet needs in rare and aggressive cancers. The company’s focus on precision medicine has fueled optimism, though its programs remain in early-stage testing. Progress in these trials has contributed …
Nuvectis Pharma revealed plans to broaden its therapeutic portfolio through a strategic in-licensing deal targeting complement-mediated diseases and oncology. The announcement came during a corporate update call, where leadership emphasized the company’s shift toward high-potential disease areas with limited treatment options. This licensing push …
AbbVie (NYSE: ABBV) announced U.S. FDA approval for Skinvive by Juvederm, a novel hyaluronic acid injectable for neck wrinkles, alongside updated Phase 3 data demonstrating durable efficacy in chronic lymphocytic leukemia.Key HighlightsAbbVie (NYSE: ABBV) received FDA approval for Skinvive by Juvederm, the first hyaluronic …
Summit Therapeutics (NASDAQ: SMMT) stands as a high-volatility biotech stock with a singular focus on its clinical pipeline. The company’s binary outcome structure means its valuation hinges on the success or failure of key drug development milestones. This profile attracts investors comfortable with elevated …
Merck (NYSE: MRK) recorded $8.23 billion in oncology revenue for the first quarter, reflecting a 12.1% rise compared with the same period a year earlier. The increase highlights sustained demand for the company’s immuno‑oncology portfolio, anchored by its PD‑1 blocker Keytruda. Market commentators view …
Insmed Incorporated (NASDAQ: INSM) is making strides in its Phase 3 TPIP program, focusing on two critical areas: pulmonary arterial hypertension (PAH) and pulmonary hypertension linked to interstitial lung disease (PH-ILD). The PALM-PAH and PALM-ILD trials are designed to establish the therapy as a …
Enliven Therapeutics has captured investor attention with its experimental oncology treatments, which aim to address unmet needs in rare and aggressive cancers. The company’s focus on precision medicine has fueled optimism, though its programs remain in early-stage testing. Progress in these trials has contributed …
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.
Please wait processing your request...